Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis says Diovan successful in Japanese patients
In the study, Diovan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use
In the study, Diovan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use
The agency believes there was not a sufficient weight of clinical evidence from the limited number of patients included in the phase II data to conclude that the
Istradefylline(KW-6002) is an anti-Parkinson’s drug that has a specific antagonistic action on the adenosine A2A receptor in the brain and is expected to provide benefit to patients with
The clinical trial is designed to evaluate the safety and clinical effects of repeat administration of SB-509 in diabetic subjects that have unmeasurable nerve conduction velocity (NCV) in
The New York Times reported that the FDA is examining an Eli Lilly document from February 2000 that showed patients taking Zyprexa in a clinical trial were three
Under the terms of the agreement Neuromed will make an upfront payment of $30 million, additional regulatory milestone payments, and will pay royalties based on sales of the
The company said it will consider several possible business structures, including partnering some or all of the programs within its immunotherapy business with companies having established programs in
Under the terms of the agreement, Royalty Pharma will purchase the first royalty interest for $2 million and will hold an option to purchase a royalty interest in
The FDA has determined the Ranbaxy formulation to be bioequivalent and therapeutically equivalent to the reference listed drug Ambien manufactured by Sanofi Aventis. Zolpidem tartrate tablets are indicated
These findings appear to contradict earlier observational studies, which found sustained use of non-steroidal anti-inflammatory drugs (NSAIDs) may have a protective effect against Alzheimer's disease. The trial involved